Drug Trial Radar · NCT05662397
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
77
Actual
Start
Mar 15, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- HotSpot Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed while on or are refractory to approved anti-PD(L)1 therapies or other standard of care.
Conditions
- Solid Tumor, Adult
- Relapsed Cancer
- Refractory Cancer
Interventions
HST-1011Drug
HST-1011 given orally
CemiplimabBiological
Cemiplimab administered via intravenous infusion in combination with HST-1011 given orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the safety and tolerability of escalating doses of single-agent HST-1011 in Part A1 or in combination with cemiplimab in Part B1.Time frame: 12 months
- To determine the Recommended Phase 2 Dose (RP2D) and schedule of HST-1011 monotherapy in Part A2 and in combination with cemiplimab in Part B2.Time frame: 12 months
Locations
14 sites in 3 countries. Site status is shown where the registry gives one.
Florida Cancer Specialists
Sarasota, Florida
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Einstein Comprehensive Cancer Center
The Bronx, New York
Providence Cancer Institute of Oregon
Portland, Oregon
Abramson Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh (UPMC), Hillman Cancer Center
Pittsburgh, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
University of Ottawa
Ottawa, Ontario, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
NEXT Oncology Barcelona IOB Hospital Quirónsalud
Barcelona, Spain
Clínica Universidad de Navarra
Madrid, Spain
NEXT Oncology Hospital Universitario Quirónsalud Madrid
Madrid, Spain
Clínica Universidad de Navarra (Pamplona)
Pamplona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.